|
Aug 27
|
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
|
|
Jun 27
|
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
|
|
Jun 24
|
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
|
|
Jun 20
|
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
|
|
Feb 28
|
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
|
|
Feb 28
|
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
|
|
Feb 23
|
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
|
|
Jan 11
|
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy
|
|
Dec 24
|
This Silence Therapeutics Insider Increased Their Holding In The Last Year
|
|
Dec 6
|
Does Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect?
|
|
Dec 1
|
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
|
|
Nov 27
|
Silence Therapeutics plc's (NASDAQ:SLN) 65% Price Boost Is Out Of Tune With Revenues
|
|
Sep 6
|
Silence Therapeutics to Participate in September Investor Conferences
|